AVEO Pharmaceuticals Total Assets 2009-2021 | AVEO

AVEO Pharmaceuticals total assets from 2009 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
AVEO Pharmaceuticals Annual Total Assets
(Millions of US $)
2020 $67
2019 $51
2018 $28
2017 $50
2016 $27
2015 $41
2014 $71
2013 $146
2012 $207
2011 $295
2010 $151
2009 $60
2008 $0
AVEO Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2021-09-30 $109
2021-06-30 $113
2021-03-31 $127
2020-12-31 $67
2020-09-30 $73
2020-06-30 $76
2020-03-31 $39
2019-12-31 $51
2019-09-30 $60
2019-06-30 $42
2019-03-31 $27
2018-12-31 $28
2018-09-30 $21
2018-06-30 $20
2018-03-31 $44
2017-12-31 $50
2017-09-30 $42
2017-06-30 $42
2017-03-31 $37
2016-12-31 $27
2016-09-30 $35
2016-06-30 $43
2016-03-31 $31
2015-12-31 $41
2015-09-30 $44
2015-06-30 $34
2015-03-31 $50
2014-12-31 $71
2014-09-30 $86
2014-06-30 $104
2014-03-31 $128
2013-12-31 $146
2013-09-30 $163
2013-06-30 $190
2013-03-31 $228
2012-12-31 $207
2012-09-30 $219
2012-06-30 $241
2012-03-31 $265
2011-12-31 $295
2011-09-30 $318
2011-06-30 $341
2011-03-31 $260
2010-12-31 $151
2010-09-30 $97
2010-06-30 $118
2010-03-31 $114
2009-12-31 $60
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
2008-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.188B $0.006B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.142B 7.97
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.170B 20.61
Biohaven Pharmaceutical Holding (BHVN) United States $6.566B 0.00
Arcus Biosciences (RCUS) United States $3.079B 0.00
Emergent Biosolutions (EBS) United States $2.259B 8.12
Myovant Sciences (MYOV) United Kingdom $1.408B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.382B 0.00
Zymeworks (ZYME) Canada $0.848B 0.00
SQZ Biotechnologies (SQZ) United States $0.318B 0.00
Ambrx Biopharma (AMAM) United States $0.306B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90